Is prolactin involved in the evolution of atherothrombotic disease?

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Pathophysiology

Background:

• Cardiovascular diseases (CVDs) are a leading cause of global mortality, with atherothrombosis being a primary driver.
• Endocrine disorders are increasingly linked to cardiovascular pathology.
• Prolactin, a pituitary hormone, is emerging as a potential factor in CVD development.

Purpose of the Study:

• To explore the potential role of prolactin in the development of atherothrombosis and cardiovascular diseases.
• To investigate whether reducing prolactin levels could be a therapeutic strategy for CVD.

Main Methods:

• Review of recent clinical and experimental studies linking prolactin to cardiovascular health.
• Speculative analysis of prolactin's mechanisms in atherothrombosis.
• Consideration of therapeutic implications for patients with hyperprolactinemia.

Main Results:

• Prolactin may influence CVD through direct effects on atherosclerotic plaques and systemic metabolic risk factors.
• The exact role of prolactin in CVD pathogenesis requires further elucidation.
• Elevated prolactin levels are associated with increased risk of atherothrombotic vascular disease.

Conclusions:

• Prolactin-lowering therapy is a potential future treatment for patients with elevated prolactin and existing or high risk of vascular disease.
• These findings may influence clinical management strategies for conditions like prolactinomas.